Real-world data (RWD) are transforming clinical research. By supplementing randomized controlled trials (RCTs), RWD can de-risk studies and improve generalizability. Innovative designs, from hybrid RCTs to registry-based trials, are gaining traction, with regulators setting clear standards for their use.
This webinar shares case studies, practical methodologies, and key considerations to help you apply RWD effectively while balancing risks and opportunities.
Speakers:
- Billy Amzal, Head of Strategic Consulting
- Wei Liu (Moderator), Associate Director of Biostatistics
Learning Points :
- When are innovative trial designs using RWD most appropriate?
- How can technical and regulatory feasibility be assessed?
- What RWD sources are most suitable?
- Which statistical methods offer the best fit in these studies?
